Results 121 to 130 of about 859,289 (399)
Успехи молекулярной онкологии, 2023 Introduction. Perioperative FLOT chemotherapy has improved prognosis in patients with locally advanced resectable gastric cancer (GC). However, in 80 % of cases, the tumor is resistant to the therapy, resulting in unnecessary toxicity and delayed ...
K. A. Oganyan +7 more
doaj +1 more source
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer
Molecular Oncology, EarlyView.We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas +15 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 87-94, January 2023., 2023 Abstract Dostarlimab (JEMPERLI) is an anti‐programmed cell death protein‐1 (PD‐1) monoclonal antibody (mAb) which is approved by the US Food and Drug Administration for patients with recurrent/advanced mismatch repair‐deficient solid tumors, including endometrial cancer, following progression on prior treatment, with approval based on data from the ...
Daren Austin +4 more
wiley +1 more source
Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer
Frontiers in Oncology, 2022 IntroductionFamily history is a high-risk factor for colorectal cancer (CRC). The risk comes not only from known germline mutations but also from the other family-related mechanisms. Uncovering them would be an important step to improve the diagnosis and
He Huang +8 more
doaj +1 more source
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. [PDF]
, 2017 PurposeTumor levels of thymidylate synthase (TS), a target of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer, have been studied as a predictive or prognostic biomarker with mixed results.Patients and methodsTumor TS levels were ...
Bertagnolli, Monica M +13 more
core +1 more source
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Molecular Oncology, EarlyView.We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi +26 more
wiley +1 more source
Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 95-109, January 2023., 2023 Abstract Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD‐1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody‐dependent phagocytosis, a potential mechanism of resistance to anti–PD‐1 therapy.
Nageshwar Budha +10 more
wiley +1 more source
Testing tumors for microsatellite instability [PDF]
European Journal of Human Genetics, 1999 The methods for determining microsatellite instability in tumors are highly heterogeneous. Recently a 5-marker panel of microsatellites was suggested for this purpose. In this review attention is drawn to the fact that microsatellite instability can be assessed by analyzing tumor DNA with a single marker, BAT-26, and that normal tissue DNA from the ...
openaire +2 more sources
Journal of the National Cancer Institute, 2004 Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a common autosomal dominant syndrome characterized by early age at onset, neoplastic lesions, and microsatellite instability (MSI).
A. Umar +22 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini +10 more
wiley +1 more source